trending Market Intelligence /marketintelligence/en/news-insights/trending/fHaxixhPE8nJmaBTp5bz7w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Emerald Organic gains license to develop Amarantus products

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Emerald Organic gains license to develop Amarantus products

Amarantus BioScience Holdings Inc. said it was selling the rights to its therapeutic products to medical cannabis company Emerald Organic Products Inc. in exchange for $100 million in preferred stock.

Amarantus has entered a binding term sheet agreement with Emerald Organic, and is expected to receive the preferred stock in 2022 plus royalties on the sales of products that are commercialized. The products are treatment candidates for Alzheimer's, attention deficit hyperactivity disorder, or ADHD, Parkinson's, severe burns and vision loss; they are called eltoprazine, engineered skin substitute, mesencephalic astrocyte-derived neurotrophic factor and PhenoGuard.

New York-based biopharmaceutical company Amarantus said members of its team will become part of Emerald's emerging life sciences unit once the transaction closes. The agreement is subject to shareholder approval of Amarantus.

Amarantus, which has never made profit or generated revenue in at least the past five years, said the agreement will help create shareholder value given its debt and capital structure. The company had $31.4 million in total liabilities at the end of 2018, according to S&P Global Market Intelligence data.

Following the agreement, Eden Prairie, Maine-based Emerald plans to start a tender offer to acquire all outstanding shares of Amarantus, subject to certain conditions.

Additionally, Amarantus and Coeptis Pharmaceuticals Inc. have agreed to not go forward with the pending merger of Elto Pharma Inc. and Coeptis. In June 2018, Amarantus said it was looking to either launch an IPO or sell its wholly owned unit Elto Pharma.

The unit, which was formed in 2017, is developing eltoprazine for treating dyskinesia — uncontrolled movement associated with treatment by Parkinson's disease drug Levodopa.